[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/26, MON) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 [ESMO 2026] 컴패스, 'DLL4xVEGF' ESMO서 논의된 "3가지 쟁점"
[https://www.biospectator.com/news/view/30176](https://www.biospectator.com/news/view/30176)

 크로스포인트, 삼양바이오팜과 항암 'siRNA' 개발 MOU
[https://www.biospectator.com/news/view/30175](https://www.biospectator.com/news/view/30175)

 메나리니, 조지아뮨서 '경구 면역항암제' 11억弗 L/I
[https://www.biospectator.com/news/view/30164](https://www.biospectator.com/news/view/30164)

 애브비, 'IL1α/1β 항체' 한선염 3상 "기대엔 못미쳐"
[https://www.biospectator.com/news/view/30162](https://www.biospectator.com/news/view/30162)

 [ESMO 2026] 알테오젠, 'ADC SC제형' 연구 포스터 "ESMO 발표"
[https://www.biospectator.com/news/view/30187](https://www.biospectator.com/news/view/30187)

 셀트리온, 1000억 규모 "자사주 추가매입 결정" 
[https://www.biospectator.com/news/view/30194](https://www.biospectator.com/news/view/30194)

 [ESMO 2026] 머크, TROP2 ADC 'PD-L1 음성' 폐암 3상 "PFS 51%↑"
[https://www.biospectator.com/news/view/30183](https://www.biospectator.com/news/view/30183)

 [ESMO 2026] 신라젠, ‘TTK/PLK1’ 고형암 1상 중간결과 “ESMO 발표”
[https://www.biospectator.com/news/view/30188](https://www.biospectator.com/news/view/30188)

 바이넥스, 'CDMO' 오송공장 "EMA GMP실사 통과" 
[https://www.biospectator.com/news/view/30195](https://www.biospectator.com/news/view/30195)

 [인사]동아쏘시오그룹, 임원승진 인사
[https://www.biospectator.com/news/view/30196](https://www.biospectator.com/news/view/30196)

 로슈, 자임웍스 ‘DLL3xCD28xCD3 TCE' 8.13억弗 L/I
[https://www.biospectator.com/news/view/30181](https://www.biospectator.com/news/view/30181)

 [ESMO 2026] 로슈, 'KRAS G12C' 직접비교 3상서 "암젠·BMS 제압" 
[https://www.biospectator.com/news/view/30179](https://www.biospectator.com/news/view/30179)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/26, MON) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)